Bakar Labs, UC Berkeley

Bakar Labs is UC Berkeley’s flagship incubator for life science startups, supporting 30 early-stage companies from around the world. Operated by QB3, Bakar Labs provides equipment, lab and office facilities, and a community of like-minded entrepreneurs to help startups grow. No UC affiliation is required to join. For information about how to join or form a partnership, visit bakarlabs.berkeley.edu.

HomeLab, UC San Diego

The university accelerator operated by LabFellows within the Center for Novel Therapeutics, HomeLab at UC San Diego has helped 47 university life science startups achieve over $1.5B in exits and funds raised over the past five years with innovation focuses ranging from cell and gene therapies to AI for drug discovery.

Stanford Institute for Stem Cell Biology & Regenerative Medicine

The Stanford Institute for Stem Cell Biology and Regenerative Medicine has a vision to be a world-leading stem cell institute, pioneering research in stem cell biology and regenerative medicine, translating breakthroughs into patient benefits, and cultivating future leaders in the field. Our researchers advance stem cell research and its applications in human health by leveraging the Stanford Medicine innovation ecosystem.

Day One

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company that was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.

Geron

Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor is approved in the US for the treatment of certain patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a Phase 3 trial in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies.

Glaukos

Glaukos is an ophthalmic medical technology & pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders & retinal disease.
Innovation is at the core of everything we do. Our mission is to truly transform vision by pioneering novel, dropless platforms that can meaningfully advance the standard of care & improve outcomes for patients suffering from sight-threatening chronic eye diseases. Our mantra “We’ll Go First” embodies our commitment & determination to take chances & push the limits of science & technology to disrupt & improve the legacy treatment paradigms in glaucoma, corneal disorders & retinal diseases.

Iovance

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy.

Erik Harris, Ultragenyx

Erik Harris is Chief Commercial Officer and EVP at Ultragenyx Pharmaceutical. At Ultragenyx, he sponsored and started the company’s formal DEI initiative and co-founded UltraMosaic, the first of seven company ERGs, which recognizes the mix of ethnicities and cultures at the company. Beyond Ultragenyx, he co-founded The Just Society to create a forum to support, empower and mentor Black professionals.

Morgan Stanton, PhD, Opal Therapeutics

Dr. Morgan Stanton is the CEO and founder of Opal Therapeutics. She holds a Ph.D. in Chemistry from Worcester Polytechnic Institute and completed her postdoctoral research at the Max Planck Institute for Intelligent Systems. Dr. Stanton is a passionate advocate for advancing women’s health and founded Opal to drive therapeutic discovery in reproductive disorders such as fibroids and endometriosis.

PJ Utz, MD, Stanford

Professor Utz is a physician-scientist and Associate Dean for Medical Student Research at Stanford Medical School. In 2000, he founded Stanford Institutes of Medicine Summer Research Program (SIMR), a summer research program for high school students in STEM, focusing on women, underrepresented minorities and economically disadvantaged students. SIMR has hosted >1,100 trainees in 25 years, promoting diversity in America’s STEM research workforce.

AltruBio

AltruBio is a clinical-stage biotechnology company developing novel Immune Checkpoint Enhancers (ICE) to address pressing medical needs of patients with autoimmune and inflammatory diseases. Its lead candidate, ALTB-268, is a tetravalent PSGL-1 agonist antibody that targets chronically activated T cells to restore immune balance. Currently ALTB-268 is being evaluated in Phase 2 studies for the treatment of ulcerative colitis.

Cellares

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), accelerates global access to life-saving cell therapies with its Cell Shuttle™ and Cell Q platforms. Offering clinical and commercial-scale manufacturing services, these automated, high-throughput technologies reduce batch prices by up to 50%, empowering developers to meet worldwide patient demand for cell therapies efficiently.

Mammoth Biosciences

Mammoth Biosciences develops ultracompact CRISPR systems aimed at creating potentially curative therapies for genetic diseases. Co-founded by Nobel laureate Jennifer Doudna, the company focuses on in vivo gene editing in difficult to reach tissues. With a wholly owned pipeline and partnerships with leading pharmaceutical and biotechnology companies, Mammoth is advancing its proprietary technology to unlock CRISPR’s transformative potential.

Bobak Azamian, MD PhD, Tarsus Pharmaceuticals

Bobby cofounded Tarsus Pharmaceuticals in 2016 and currently serves as CEO and Chairman. Under his leadership, Tarsus secured FDA approval for XDEMVY® (lotilaner ophthalmic solution) 0.25%, the first and only FDA-approved treatment for Demodex blepharitis. He currently serves on the boards of Vibrato Medical and Osanni Bio (Chairman). Bobby holds degrees from Harvard Medical School, Oxford University and Rice University.

David Persing, MD PhD, Cepheid

Dr. David Persing, MD, Ph.D., is EVP/Chief Medical Officer at Cepheid, where he has focused on advancements in molecular diagnostics for addressing the global challenges of emerging Infectious diseases. He has authored over 300 peer reviewed publications and is an inventor on 33 US patents. Recognized for his impact on COVID-19 diagnostics, Dave was recognized as one of the top 22 most influential scientists by Fierce Pharma in 2020.

Matthew Rabinowitz, PhD, Natera

Matthew Rabinowitz, co-founder and Executive Chairman of Natera, previously served as its CEO from 2005 – 2018. With a Ph.D. from Stanford, he’s led groundbreaking research in non-invasive prenatal testing and oncology. Dr. Rabinowitz has authored >100 patents and numerous academic papers in top-tier journals like Nature and JAMA Oncology, and received the World Economic Forum Technology Pioneer Award twice.

Moon Surgical

Moon Surgical is shaping the future of the OR with its efficient, sustainable, and digitalized Maestro System. Maestro empowers surgeons with precise control and actionable insights, improving workflow, reducing variability, and aiming to enhance patient outcomes.

Moon Surgical. Inspiring and Innovating the Art of Surgery.

Osso VR

Osso VR creates award-winning XR training experiences used by leading healthcare companies and hospital systems. Its core product, Osso Enterprise, offers customized, immersive medical training in a risk-free, collaborative environment. Integrated analytics measure performance outcomes, improving healthcare professionals’ skills and leading to better patient results.

Cooler Heads

Cooler Heads’ Amma is the only solution that makes it profitable for infusion centers to offer chemotherapy patients scalp cooling so they can keep their hair. Since they launched at the end of 2022, over 70% of the health systems offering Amma to their patients had never had a scalp cooling program before.